EGFR (S768I)
Sign in to save this workspaceEGFR · Variant type: point · HGVS: p.S768I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Canertinib | 100.0% | 0.0% | 96.49 |
| 2 | Neratinib | 100.0% | 0.0% | 93.18 |
| 3 | Mobocertinib | 100.0% | 0.0% | 97.22 |
| 4 | Lazertinib | 99.9% | 0.1% | 97.47 |
| 5 | Pralsetinib | 99.9% | 0.1% | 93.43 |
| 6 | Erlotinib | 99.9% | 0.1% | 99.75 |
| 7 | Vandetanib | 99.6% | 0.4% | 95.74 |
| 8 | Pacritinib | 83.0% | 17.0% | 88.64 |
| 9 | Defactinib | 76.8% | 23.2% | 92.68 |
| 10 | Gilteritinib | 76.3% | 23.6% | 88.97 |
| 11 | Alpelisib | 72.4% | 27.6% | 97.22 |
| 12 | Pemigatinib | 50.6% | 49.4% | 98.23 |
| 13 | Zanubrutinib | 46.5% | 53.5% | 98.24 |
| 14 | Capmatinib | 39.6% | 60.4% | 99.75 |
| 15 | Darovasertib | 35.8% | 64.2% | 96.99 |
| 16 | Pirtobrutinib | 33.6% | 66.4% | 99.49 |
| 17 | Apatinib | 20.3% | 79.7% | 97.73 |
| 18 | Avapritinib | 19.5% | 80.5% | 97.73 |
| 19 | Pexidartinib | 18.6% | 81.4% | 99.49 |
| 20 | Tivozanib | 17.0% | 83.0% | 92.42 |
| 21 | Tenalisib | 14.0% | 86.0% | 97.98 |
| 22 | Ripretinib | 9.3% | 90.7% | 92.95 |
| 23 | Umbralisib | 7.3% | 92.7% | 98.74 |
| 24 | Fedratinib | 7.2% | 92.8% | 96.21 |
| 25 | Abemaciclib | 7.1% | 92.9% | 91.48 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Canertinib | 100.0% | 98.4% | +1.6% |
| Neratinib | 100.0% | 100.0% | +0.0% |
| Mobocertinib | 100.0% | 100.0% | +0.0% |
| Lazertinib | 99.9% | 100.0% | -0.1% |
| Pralsetinib | 99.9% | 99.1% | +0.8% |
| Erlotinib | 99.9% | 99.4% | +0.4% |
| Vandetanib | 99.6% | 99.3% | +0.3% |
| Pacritinib | 83.0% | — | — |
| Defactinib | 76.8% | 94.6% | -17.8% |
| Gilteritinib | 76.3% | 91.0% | -14.7% |
| Alpelisib | 72.4% | — | — |
| Pemigatinib | 50.6% | — | — |
| Zanubrutinib | 46.5% | 88.2% | -41.7% |
| Capmatinib | 39.6% | — | — |
| Darovasertib | 35.8% | — | — |
| Pirtobrutinib | 33.6% | — | — |
| Apatinib | 20.3% | — | — |
| Avapritinib | 19.5% | — | — |
| Pexidartinib | 18.6% | — | — |
| Tivozanib | 17.0% | — | — |
| Tenalisib | 14.0% | — | — |
| Ripretinib | 9.3% | — | — |
| Umbralisib | 7.3% | — | — |
| Fedratinib | 7.2% | — | — |
| Abemaciclib | 7.1% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| Esophageal Cancer | Stomach/Digestive Tract | ref |
| carcinoma_lung | Lung | ref |
| adrenal_cortical_carcinoma_adrenal_gland | Adrenal | ref |
| glioma_central_nervous_system | Brain/CNS | ref |
| carcinoma_biliary_tract | Biliary Tract | ref |
| mesothelioma_pleura | Lung | ref |
| carcinoma_oesophagus | Stomach/Digestive Tract | ref |
| carcinoma_breast | Breast | ref |
| carcinoma_prostate | Prostate | ref |
| BRCA-US | Breast | ref |
| LUAD-US | Lung | ref |
| BRCA | Breast | ref |
| LUAD | Lung | ref |
| ESCA | Stomach/Digestive Tract | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.2ms